AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28017642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Ebola vaccine at 4·0×1010 viral particles (low dose) after boost
Number of subjects: 120
Study 28017642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Ebola vaccine at 1·6×1011 viral particles (high dose) after boost
Number of subjects: 120
Study 28017642 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccine groups (low and high dose)
Number of subjects: 120
Study 26577514 — intervention group
Group type: EXPERIMENTAL
Intervention: Program participation
Number of subjects: 59
Study 24036915 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli designed to elicit variable V1 response spread, details on dosage and duration not available.
Number of subjects: 0
Study 22078490 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured motivational intervention including smoking cessation advice and spirometry information
Number of subjects: 600
Study 22078490 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice (control group)
Number of subjects: 600
Study 18830816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 9444
Study 18830816 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Tamoxifen
Number of subjects: 9444
Study 18830816 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 9444
Study 18830816 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 9444
Study 18323331 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg, twice daily (BID)
Number of subjects: 0
Study 18323331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18323331 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 0
Study 15482038 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight relapse-prevention booklets mailed over 1 year
Number of subjects: 431
Study 15482038 — intervention group
Group type: COMPARATOR
Intervention: Single relapse-prevention booklet mailed over 1 year
Number of subjects: 431
Study 15482038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-content interventions (eight booklets)
Number of subjects: 431
Study 15482038 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of contact (not specified)
Number of subjects: 431
Study 11536065 — intervention group
Group type: EXPERIMENTAL
Intervention: anterior rhinomanometry (aR)
Number of subjects: 17
Study 11536065 — intervention group
Group type: EXPERIMENTAL
Intervention: impulse-oscillometric rhinometry (IOS)
Number of subjects: 17
Study 9622116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood salvage (IOBS)
Number of subjects: 61
Study 8172506 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative kinematic gait variables
Number of subjects: 17
Study 3420976 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCV vaccine
Number of subjects: 161
Study 3420976 — intervention group
Group type: EXPERIMENTAL
Intervention: FBKC vaccine
Number of subjects: 161
Study 3420976 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEC vaccine
Number of subjects: 161
Study 3420976 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV vaccine
Number of subjects: 161
Study 3420976 — intervention group
Group type: EXPERIMENTAL
Intervention: PDEV vaccine
Number of subjects: 161
Study 3420976 — intervention group
Group type: COMPARATOR
Intervention: 2-1-1 schedule
Number of subjects: 161
Study 29316338 — intervention group
Group type: EXPERIMENTAL
Intervention: VoiceDiab system supporting bolus calculation
Number of subjects: 44
Study 29316338 — intervention group
Group type: COMPARATOR
Intervention: Unsupported group (patients or caregivers calculated boluses)
Number of subjects: 44
Study 27211272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 146
Study 27211272 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 146
Study 24330076 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized light noncontact dermoscopy (PNCD)
Number of subjects: 45
Study 24330076 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpolarized light contact dermoscopy (NPCD)
Number of subjects: 45
Study 24330076 — intervention group
Group type: COMPARATOR
Intervention: Conventional stereomicroscope nailfold capillaroscopy (SNFC)
Number of subjects: 45
Study 24341101 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuganyiyang Capsule combined with tamsulosin hydrochloride sustained release tablets and prostat tablets
Number of subjects: 80
Study 24341101 — intervention group
Group type: COMPARATOR
Intervention: tamsulosin hydrochloride and prostat only
Number of subjects: 80
Study 21176233 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and personalised feedback via computer (e-SBI)
Number of subjects: 7
Study 21176233 — intervention group
Group type: COMPARATOR
Intervention: No further contact until follow-up (control)
Number of subjects: 7
Study 17676392 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolytic celiac plexus block (NCPB) guided by computerized tomography (CT)
Number of subjects: 56
Study 17676392 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 56
Study 17676392 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolytic celiac plexus block (NCPB)
Number of subjects: 56
Study 16080273 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan capsule preparation (test)
Number of subjects: 20
Study 16080273 — intervention group
Group type: COMPARATOR
Intervention: rizatriptan tablet (reference)
Number of subjects: 20
Study 12512986 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional Crest Whitestrips (6.5% hydrogen peroxide), total contact time 21 hours
Number of subjects: 69
Study 12512986 — intervention group
Group type: COMPARATOR
Intervention: Nite White Excel2 (custom tray-based system using hydrogen and carbamide peroxide, 10% carbamide peroxide equivalent), total contact time 28 hours
Number of subjects: 69
Study 10342501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 540)
Number of subjects: 1062
Study 10342501 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 522)
Number of subjects: 1062
Study 10342501 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1062
Study 8949806 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 with thiopentone 5 mg kg‐1
Number of subjects: 100
Study 8949806 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 with propofol 2.5 mg kg‐1
Number of subjects: 100
Study 8949806 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 with propofol 2.5 mg kg‐1 and alfentanil 20 micrograms kg‐1
Number of subjects: 100
Study 8949806 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 with thiopentone 5 mg kg‐1 and alfentanil 20 micrograms kg‐1
Number of subjects: 100
Study 8949806 — intervention group
Group type: COMPARATOR
Intervention: Control group: Thiopentone followed by suxamethonium
Number of subjects: 100
Study 8949806 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 100
Study 8949806 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium without alfentanil
Number of subjects: 100
Study 8949806 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with alfentanil
Number of subjects: 100
Study 1921398 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined application of hyperthermia and intra-hepato-arterial (IHA) chemotherapy with cisplatinum and 5-fluorouracil
Number of subjects: 14
Study 1921398 — intervention group
Group type: COMPARATOR
Intervention: IHA chemotherapy with the same chemotherapeutic regimen
Number of subjects: 14
Study 10256780 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual instruction
Number of subjects: 0
Study 10256780 — intervention group
Group type: COMPARATOR
Intervention: Group instruction
Number of subjects: 0
Study 30638439 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) training on 1 extremity
Number of subjects: 26
Study 30638439 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) training
Number of subjects: 26
Study 30638439 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) training on nontourniquet extremity
Number of subjects: 26
Study 30638439 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 29800214 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced adenoma (≥1 cm, high-grade dysplasia, or tubulovillous or villous histology)
Number of subjects: 15935
Study 29800214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadvanced adenoma (<1 cm without advanced histology)
Number of subjects: 15935
Study 29800214 — intervention group
Group type: COMPARATOR
Intervention: No adenoma
Number of subjects: 15935
Study 29800214 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced adenoma
Number of subjects: 15935
Study 29800214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadvanced adenoma
Number of subjects: 15935
Study 26638219 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy‐Adolescent Skills Training (IPT‐AST)
Number of subjects: 186
Study 26638219 — intervention group
Group type: COMPARATOR
Intervention: Group Counseling (GC)
Number of subjects: 186
Study 24480179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 60
Study 24480179 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 60
Study 22668911 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (PGA) sutures
Number of subjects: 1100
Study 22668911 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin staples (SS)
Number of subjects: 1100
Study 22668911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon sutures
Number of subjects: 1100
Study 22668911 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupture of membranes >12 hours
Number of subjects: 1100
Study 22668911 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery duration
Number of subjects: 1100
Study 22668911 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 1100
Study 22668911 — intervention group
Group type: EXPERIMENTAL
Intervention: Time period of observation
Number of subjects: 1100
Study 19735494 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stimulation of the radial nerve (Radial group)
Number of subjects: 70
Study 19735494 — intervention group
Group type: COMPARATOR
Intervention: Dual stimulation technique (Dual group)
Number of subjects: 70
Study 17514537 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 1 (T1): 2,092 kJ/day (500 kcal/day) peanuts for 8 weeks
Number of subjects: 0
Study 17514537 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 2 (T2): 2,092 kJ/day (500 kcal/day) peanuts for 3 weeks
Number of subjects: 0
Study 17514537 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 3 (T3): Substitution of 2,092 kJ/day fat with energy from peanuts
Number of subjects: 0
Study 16813878 — intervention group
Group type: EXPERIMENTAL
Intervention: difluoromethylornithine
Number of subjects: 454
Study 16813878 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 454
Study 14605042 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 50 mg IM injection on days 1, 15, 29, and 43
Number of subjects: 63
Study 14605042 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 50 mg IM injection
Number of subjects: 63
Study 14605042 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL of arachis oil)
Number of subjects: 63
Study 11040170 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amethocaine gel (4% w/w, 1.5 g applied under occlusion for one hour)
Number of subjects: 40
Study 11040170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9363140 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided percutaneous chest catheters for draining pleural effusions
Number of subjects: 0
Study 9363140 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic agents for promoting drainage of loculated, viscous pleural fluid
Number of subjects: 0
Study 9363140 — intervention group
Group type: COMPARATOR
Intervention: Chest tube drainage method
Number of subjects: 0
Study 1430084 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/hMG/hCG
Number of subjects: 26
Study 1430084 — intervention group
Group type: COMPARATOR
Intervention: hMG/hCG
Number of subjects: 26
Study 1430084 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG/hCG or GH/hMG/hCG
Number of subjects: 26
Study 1430084 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal spontaneous pregnancies
Number of subjects: 26
Study 1430084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological amounts of hMG
Number of subjects: 26
Study 6476587 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulphate (18 mg nebulized during tidal breathing)
Number of subjects: 5
Study 6476587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30166639 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-sweetened beverages
Number of subjects: 24
Study 30166639 — intervention group
Group type: COMPARATOR
Intervention: Fructose-sweetened beverages
Number of subjects: 24
Study 30166639 — intervention group
Group type: COMPARATOR
Intervention: High-fructose corn syrup-sweetened beverages
Number of subjects: 24
Study 30166639 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight participants
Number of subjects: 24
Study 30680404 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom combined with case‐based learning (CBL)
Number of subjects: 51
Study 30680404 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 51
Study 27169342 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted education and new sizes of tubes of non-rinse skin cleanser in three clinical areas.
Number of subjects: 5
Study 27169342 — intervention group
Group type: COMPARATOR
Intervention: Targeted education only in one clinical area.
Number of subjects: 5
Study 27169342 — intervention group
Group type: COMPARATOR
Intervention: No education or new sized tubes in one clinical area.
Number of subjects: 5
Study 25069747 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) 75 mg/m² for 21 consecutive days followed by a 7-day rest for up to 6 cycles or until progression
Number of subjects: 53
Study 25069747 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 53
Study 25069747 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Number of subjects: 53
Study 22372386 — intervention group
Group type: EXPERIMENTAL
Intervention: 1550-nm fractional photothermolysis (FP)
Number of subjects: 18
Study 22372386 — intervention group
Group type: COMPARATOR
Intervention: 15% trichloroacetic acid (TCA) peel
Number of subjects: 18
Study 22372386 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-inflammatory hyperpigmentation
Number of subjects: 18
Study 22372386 — intervention group
Group type: EXPERIMENTAL
Intervention: FP treatment
Number of subjects: 18
Study 22372386 — intervention group
Group type: COMPARATOR
Intervention: TCA peeling
Number of subjects: 18
Study 20570343 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intraoperative radiotherapy
Number of subjects: 2232
Study 20570343 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy
Number of subjects: 2232
Study 17913440 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Education plus Video Education (SE + VE)
Number of subjects: 112
Study 17913440 — intervention group
Group type: COMPARATOR
Intervention: Standard Education (SE)
Number of subjects: 112
Study 16541716 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training (BF) with anorectal manometry and surface EMG, four day-by-day sessions.
Number of subjects: 22
Study 16541716 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (control group).
Number of subjects: 22
Study 11897923 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg valdecoxib
Number of subjects: 0
Study 11897923 — intervention group
Group type: COMPARATOR
Intervention: 50 mg rofecoxib
Number of subjects: 0
Study 11897923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10052485 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR (360 mg)
Number of subjects: 11
Study 10052485 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril (4 mg)
Number of subjects: 11
Study 10052485 — intervention group
Group type: COMPARATOR
Intervention: Vera/tran (180 mg verapamil SR and 2 mg trandolapril)
Number of subjects: 11
Study 7671948 — intervention group
Group type: EXPERIMENTAL
Intervention: partial whey-hydrolysate formula
Number of subjects: 58
Study 7671948 — intervention group
Group type: COMPARATOR
Intervention: regular cow's milk formula
Number of subjects: 58
Study 1787608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty suppositories (FS)
Number of subjects: 49
Study 1787608 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin capsulated suppositories (GCS)
Number of subjects: 49
Study 1787608 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 49
Study 1787608 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 49
Study 1787608 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 49
Study 7047770 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride (average dose, 105 mg)
Number of subjects: 16
Study 7047770 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride (0.24 mg)
Number of subjects: 16
Study 7047770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31402471 — intervention group
Group type: EXPERIMENTAL
Intervention: One preoperative autologous blood donation (PAD)
Number of subjects: 102
Study 31402471 — intervention group
Group type: EXPERIMENTAL
Intervention: Two preoperative autologous blood donations (PAD)
Number of subjects: 102
Study 31402471 — intervention group
Group type: EXPERIMENTAL
Intervention: BM harvest
Number of subjects: 102
Study 31402471 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of Hb levels at day +1
Number of subjects: 102
Study 28637880 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed tunnel CO2 EVH
Number of subjects: 300
Study 28637880 — intervention group
Group type: EXPERIMENTAL
Intervention: Open tunnel CO2 EVH
Number of subjects: 300
Study 28637880 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvesting
Number of subjects: 300
Study 26933841 — intervention group
Group type: EXPERIMENTAL
Intervention: Early deworming at enrollment
Number of subjects: 250
Study 26933841 — intervention group
Group type: EXPERIMENTAL
Intervention: Early deworming in children with positive Ascaris status
Number of subjects: 250
Study 26933841 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming (timing not specified)
Number of subjects: 250
Study 24709170 — intervention group
Group type: EXPERIMENTAL
Intervention: Transulnar approach (TUA)
Number of subjects: 535
Study 24709170 — intervention group
Group type: COMPARATOR
Intervention: Transradial approach (TRA)
Number of subjects: 535
Study 23071207 — intervention group
Group type: EXPERIMENTAL
Intervention: School-Wide Positive Behavioral Interventions and Supports (SWPBIS)
Number of subjects: 12344
Study 23071207 — intervention group
Group type: EXPERIMENTAL
Intervention: SWPBIS
Number of subjects: 12344
Study 19237632 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (subcutaneous 180 mg every 4 weeks or every 12 weeks)
Number of subjects: 111
Study 19237632 — intervention group
Group type: COMPARATOR
Intervention: IV Bisphosphonates (IV BP) every 4 weeks
Number of subjects: 111
Study 17279340 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer rejection (lowest total 'likeability' score)
Number of subjects: 142
Study 17279340 — intervention group
Group type: COMPARATOR
Intervention: Peer success (highest score)
Number of subjects: 142
Study 17279340 — intervention group
Group type: COMPARATOR
Intervention: Control peer evaluation condition
Number of subjects: 142
Study 16053664 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m² i.v. weekly for 6 weeks) + celecoxib (400 mg p.o. b.i.d. continuously)
Number of subjects: 58
Study 16053664 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel + celecoxib
Number of subjects: 58
Study 11988252 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand gels
Number of subjects: 0
Study 11988252 — intervention group
Group type: COMPARATOR
Intervention: Hand rinses
Number of subjects: 0
Study 9696223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal subdiaphragmatic 0.5% lidocaine and trocar site infiltration of 0.5% bupivacaine
Number of subjects: 61
Study 9696223 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 61
Study 7988858 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery chair
Number of subjects: 140
Study 7988858 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 140
Study 2656936 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1,000 mg of calcium carbonate daily for three months)
Number of subjects: 33
Study 2656936 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for three months)
Number of subjects: 33
Study 2656936 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 33
Study 31004462 — intervention group
Group type: EXPERIMENTAL
Intervention: +SS (SPF-50 sunscreen)
Number of subjects: 27
Study 31004462 — intervention group
Group type: EXPERIMENTAL
Intervention: +SW (simulated sweat)
Number of subjects: 27
Study 31004462 — intervention group
Group type: COMPARATOR
Intervention: UVR only
Number of subjects: 27
Study 31004462 — intervention group
Group type: COMPARATOR
Intervention: CON (non-exposed control)
Number of subjects: 27
Study 29025850 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of tranexamic acid (TXA) intravenously
Number of subjects: 58
Study 29025850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline) intravenously
Number of subjects: 58